Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 551-559

  Bellamy, W T ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FETAL LIVER KINASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; BONE MARROW BIOPSY; BURKITT LYMPHOMA; CANCER GROWTH; HISTIOCYTIC LYMPHOMA; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TUMOR VASCULARIZATION;

EID: 0035207927     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90023-5     Document Type: Article

References (56)

1. Multiple myeloma
2. Plasma cell neoplasms, in DeVita VT
3. Cancer statistics 2001
4. Management of multiple myeloma today
5. Clinical applications of research on angiogenesis
6. Bone marrow angiogenesis and progression in multiple myeloma
7. Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1 and CD44
8. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study
9. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
10. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
11. Expression of vascular endothelial growth factor (VEGF) and its receptors in hematopoietic malignancies
12. Expression of vascular endothelial cell growth factor (VEGF) and its receptors in non-Hodgkin's lymphoma
13. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
14. Angiogenesis in myelodysplastic syndromes
15. Vascular endothelial cell growth factor (VEGF) is an autocrine promoter of abnormal localized immature myeloid precursors (ALIP) and leukemia progenitor formation in myelodysplastic syndromes
16. Antitumor activity of thalidomide in refractory multiple myeloma
17. Thalidomide in the treatment of relapsed multiple myeloma
18. Thalidomide is an inhibitor of angiogenesis
19. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeabiltty, and angiogenesis
20. Regulation of angiogenesis via vascular endothelial growth factor receptors
21. Molecular biology of the VEGF and the VEGF receptor family
22. Vascular endothelial growth factor and the regulation of angiogenesis
23. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
24. KDR receptor: A key marker defining hematopoietic stem cells
25. Role of the Fltl receptor tyrosme kinase in regulating the assembly of vascular endotbelium
26. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice
27. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
28. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
29. Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma
30. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
31. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
32. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
33. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL-1 acting as an antiapoptotic factor
34. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
35. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer
36. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
37. Multiple myeloma
38. Interleukin-6 in human multiple myeloma
39. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
40. Autocrine generation and requirement of BSF/IL-6 for multiple myelomas
41. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
42. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping apoptosis
43. Interleukin-6 inhibits apoptosis of malignant plasma cells
44. Expression of Fas/Apo-1 (CD-95) and apoptosis in tumor cells from patients with plasma cell disorders
45. Mechanisms of bone destruction in multiple myeloma
46. Bone disease in myeloma
47. Interleukin-1 beta rather than lymphotoxin as a major bone resorbing activity in human multiple myeloma
48. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors
49. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma
50. Expression levels of GP-130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6 type cytokines
51. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation
52. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts
53. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
54. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
55. Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression
56. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents